Valneva laboratory regains momentum in the late afternoon, in a rising Parisian market. The stock erases some of its recent slide, after weeks marked by a capital increase and deteriorated quarterly results. Today's rebound brings the biotech back above a technical threshold.
The stock crosses back above its MM20 at €2.46 and marks one of the strongest gains in the SBF 120
Valneva's stock is up 4.04% at €2.68, among the strongest increases in the SBF 120, while the broader index is up 0.77% in session. This movement brings the weekly gain to 9.57%, after a quarter marked by a decline of nearly 43%. The stock has moved back above its 20-day moving average (€2.46), with a gap of nearly 9%. However, it remains below the MM50 at €2.81 and significantly under the MM200 at €3.82, indicating that the medium-term trend has not reversed. The RSI at 47 indicates a neutral configuration, without excessive selling or buying pressure. The resistance at €2.74, close to the current price, is now the next level to watch.
The day's rebound comes in the context of digesting recent announcements
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Today's rebound occurs in the context of digesting recent announcements. The first quarter 2026 accounts, published on May 13, showed a 37% decline in revenue and a net loss of 32.1 million euros, compared to 9.2 million a year earlier. On this occasion, the company announced a reorganization plan aimed at reducing its operational costs by 25 to 35% and its global workforce by 10 to 15%. The 2026 revenue guidance was adjusted to a range of 135 to 150 million euros, with a focus on key strategic projects. Earlier, at the end of April, Valneva had completed a reserved offer of 84 million euros, the dilutive effect of which weighed on the stock price in the weeks that followed. Next appointment: the general meeting on June 1, 2026.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
